At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 489 enrolled
Drug / intervention
Abatacept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Abatacept and Placebo for Psoriatic Arthritis. Completed, enrolled 489 participants across 82 sites in 17 countries.
Detailed Summary
The purpose of this study is to compare subcutaneous Abatacept to placebo in the treatment of psoriatic arthritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesArgentina, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Greece, Israel, Italy, Mexico, Peru, Poland, South Africa, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 2013
Enrollment StartJun 2013
Primary CompletionJul 2015
Study CompletionJun 2020
TodayJul 2026
First PostedMay 23, 2013
Enrollment StartJun 17, 2013
Primary CompletionJul 14, 2015
Study CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 13.1 years ago
Interventions
Abataceptdrug
Placebodrug